welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Rectal Epithelial Apoptosis in Familial Adenomatous Polyposis Patients Treated with SulindacBACKGROUND : Sulindac regresses colorect...
-
Gliotoxin Inhibits Proliferation and Induces Apoptosis in Colorectal Cancer CellsThe discovery of new bioactive compounds...
-
Eicosapentaenoic Acid Reduces Rectal Polyp Number and Size in Familial Adenomatous PolyposisOBJECTIVE : The omega-3 polyunsaturated ...
-
Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis PatientsThe purpose of this study is to assess i...
-
Label-Free Global Serum Proteomic Profiling Reveals Novel Celecoxib-Modulated Proteins in Familial Adenomatous Polyp...Celecoxib, a selective inhibitor of cycl...
-
Surgical Considerations in FAP-related Pouch Surgery: Could We do Better?The ileoanal pouch has become the standa...
-
Comparison of Proctocolectomy and Ileal Pouch-Anal Anastomosis to Colectomy and Ileorectal Anastomosis in Familial A...Prophylactic surgical options for famili...